Hepatitis B, Hepatitis C, HIV Infections
Conditions
Brief summary
People in Administrative Detention Centers often come from areas of medium or high HIV, hepatitis C & B endemic, and are often unaware of their serological status. Currently, HIV, hepatitis C & B screening is not systematically performed at the CRA of Nîmes, and when performed, serological tests are used. The main disadvantage of this method is the length of time it takes to obtain the results, with subjects frequently discharged before receiving their results. To improve the care of these vulnerable persons, the aim of this study is to estimate the prevalence of HIV, hepatitis C and hepatitis B in the detainees of the administrative detention center of Nîmes, by systematically screening with a rapid diagnosis test. In case of a positive rapid diagnosis test test, a serology test will confirm the rapid diagnosis test result.
Interventions
DIAGNOSTIC_TESTRapid diagnosis test against HIV and hepatitis C and B
combined Insti VIH® + Toyo VHC®, then First response Ag Hbs tested on capillary blood sample
Sponsors
Centre Hospitalier Universitaire de Nīmes
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* The patient must have given their free and informed oral consent * Patient detained in the Nîmes Administrative Detention Center Exclusion Criterion • It is impossible to give the subject informed information
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of Hepatitis B infection in detainees at the Nîmes Administrative Detention Center | Inclusion | Rapid diagnosis test: Positive/negative |
| Prevalence of HIV infection in detainees at the Nîmes Administrative Detention Center | Inclusion | Rapid diagnosis test: Positive/negative |
| Prevalence of Hepatitis C infection in detainees at the Nîmes Administrative Detention Center | Inclusion | Rapid diagnosis test: Positive/negative |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Participant previous transfusion | Inclusion | Yes/no |
| Intravenous drug use | Inclusion | Yes/no |
| Intranasal drug use | Inclusion | Yes/no |
| Shared drug paraphernalia | Inclusion | Yes/no |
| Knowledge of HIV, Hep C and Hep B status | Inclusion | Yes/no |
| Participant with piercings | Inclusion | If yes, professional done or not |
| Participant with tattoos | Inclusion | If yes, professional done or not |
| Feasibility of screening | End of study (1 year) | % of subjects with available samples (ie no subject refusal, subjects arriving at weekend or holiday, study not offered on a weekday, technical problem with test interpretation) |
| Acceptability of the screening | End of study (1 year) | % of subjects giving samples |
| Non-protected sexual activity | Inclusion | Yes/no |
| Prevalence of co-infections between HIV, Hepatitis C and Hepatitis B | Inclusion | Yes or no for co-infection (HIV-Hep C / HIV-Hep B / HepC-HepB / Hiv-HepC-HepB) |
| Participant country of origin | Inclusion | Country name |
Countries
France
Outcome results
None listed